Harrison, Stephen A.

Challenges and opportunities in NASH drug development

Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 353

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

Patel, K., Harrison, S. A., Elkhashab, M., Trotter, J. F., Herring, R., Rojter, S. E., Kayali, Z., Wong, V. W., Greenbloom, S., Jayakumar, S., et al. (2020) · Hepatology

Liver Disease Diagnosis and TreatmentHepatitis C virus research

Cited by 347

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

Loomba, R., Kayali, Z., Noureddin, M., Ruane, P., Lawitz, E. J., Bennett, M., Wang, L., Harting, E., Tarrant, J. M., McColgan, B. J., et al. (2018) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 340

Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort

Harrison, S. A., Gawrieh, S., Roberts, K., Lisanti, C. J., Schwope, R. B., Cebe, K. M., Paradis, V., Bedossa, P., Aldridge Whitehead, J. M., Labourdette, A., et al. (2021) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 293

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

Gastaldelli, A., Harrison, S. A., Belfort-Aguilar, R., Hardies, L. J., Balas, B., Schenker, S., & Cusi, K. (2009) · Hepatology

Liver Disease Diagnosis and TreatmentAdipokines, Inflammation, and Metabolic Diseases

Cited by 285

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

Harrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., et al. (2021) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 280

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

Anstee, Q. M., Lawitz, E. J., Alkhouri, N., Wong, V. W., Romero‐Gomez, M., Okanoue, T., Trauner, M., Kersey, K., Li, G., Han, L., et al. (2019) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 277

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Harrison, S. A., Frias, J. P., Neff, G., Abrams, G. A., Lucas, K. J., Sanchez, W., Gogia, S., Sheikh, M. Y., Behling, C., Bedossa, P., et al. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentFibroblast Growth Factor Research

Cited by 276

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis

Harrison, S. A., Rossi, S. J., Paredes, A. H., Trotter, J. F., Bashir, M. R., Guy, C. D., Banerjee, R., Jaros, M. J., Owers, S., Baxter, B. A., et al. (2020) · Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 262

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

Vacca, M., Kamzolas, I., Harder, L. M., Oakley, F., Trautwein, C., Hatting, M., Ross, T., Bernardo, B., Oldenburger, A., Hjuler, S. T., et al. (2024) · Nature Metabolism

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease

Cited by 262

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis

Harrison, S. A., Goodman, Z., Jabbar, A., Vemulapalli, R., Younes, Z. H., Freilich, B., Sheikh, M. Y., Schattenberg, J. M., Kayali, Z., Zivony, A., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 260

Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease

Lin, H., Lee, H. W., Yip, T. C.-F., Tsochatzis, E., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M.-H., Hagström, H., Boursier, J., et al. (2024) · JAMA

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 250

Mixed lineage kinase 3 mediates release of C‐X‐C motif ligand 10–bearing chemotactic extracellular vesicles from lipotoxic hepatocytes

Ibrahim, S. H., Hirsova, P., Tomita, K., Bronk, S. F., Werneburg, N. W., Harrison, S. A., Goodfellow, V. S., Malhi, H., & Gores, G. J. (2016) · Hepatology

Extracellular vesicles in diseaseLiver Disease Diagnosis and Treatment

Cited by 232

Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

Vali, Y., Lee, J., Boursier, J., Petta, S., Wonders, K., Tiniakos, D., Bedossa, P., Geier, A., Francque, S., Allison, M., et al. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 224

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

Loomba, R., Mohseni, R., Lucas, K. J., Gutierrez, J. A., Perry, R. G., Trotter, J. F., Rahimi, R. S., Harrison, S. A., Ajmera, V., Wayne, J. D., et al. (2021) · Gastroenterology

Liver Disease Diagnosis and TreatmentCancer, Lipids, and Metabolism

Cited by 220

Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery

Barker, K. B., Palekar, N. A., Bowers, S. P., Goldberg, J. E., Pulcini, J. P., & Harrison, S. A. (2006) · The American Journal of Gastroenterology

Bariatric Surgery and OutcomesLiver Disease Diagnosis and Treatment

Cited by 218

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study

Harrison, S. A., Alkhouri, N., Davison, B. A., Sanyal, A., Edwards, C., Colca, J. R., Lee, B. H., Loomba, R., Cusi, K., Kolterman, O., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 211

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Harrison, S. A., Bashir, M., Moussa, S. E., McCarty, K., Pablo Frias, J., Taub, R., & Alkhouri, N. (2021) · Hepatology Communications

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 197

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial

Hirschfield, G. M., Chazouillères, O., Drenth, J. P., Thorburn, D., Harrison, S. A., Landis, C. S., Mayo, M. J., Muir, A. J., Trotter, J. F., Leeming, D. J., et al. (2019) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 187

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

Newsome, P., Francque, S., Harrison, S., Ratziu, V., Van Gaal, L., Calanna, S., Hansen, M., Linder, M., & Sanyal, A. (2019) · Alimentary Pharmacology & Therapeutics

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 186

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial

Torres, D. M., Jones, F. J., Shaw, J. C., Williams, C. D., Ward, J. A., & Harrison, S. A. (2011) · Hepatology

Liver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Cited by 183

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis

Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Abdelmalek, M. F., Ding, D., Han, L., Jia, C., Huss, R. S., Chung, C., et al. (2022) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 171

Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study

Rinella, M. E., Dufour, J.-F., Anstee, Q. M., Goodman, Z., Younossi, Z., Harrison, S. A., Loomba, R., Sanyal, A. J., Bonacci, M., Trylesinski, A., et al. (2022) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 164

Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis

Andersson, A., Kelly, M., Imajo, K., Nakajima, A., Fallowfield, J. A., Hirschfield, G., Pavlides, M., Sanyal, A. J., Noureddin, M., Banerjee, R., et al. (2022) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentAdvanced MRI Techniques and Applications

Cited by 148